Alvotech (NASDAQ:ALVO) Upgraded at Zacks Research

Zacks Research upgraded shares of Alvotech (NASDAQ:ALVO) from a strong sell rating to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Morgan Stanley set a $10.00 price target on Alvotech in a report on Wednesday, December 3rd. Barclays started coverage on Alvotech in a research report on Monday, December 8th. They set an “underweight” rating and a $5.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research note on Wednesday, January 21st. Finally, Wall Street Zen downgraded Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.60.

Alvotech Stock Down 1.4%

NASDAQ:ALVO opened at $3.53 on Thursday. The stock has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $5.86. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of 35.30 and a beta of 0.16. Alvotech has a 1-year low of $3.42 and a 1-year high of $11.85.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.50). The firm had revenue of $173.20 million for the quarter, compared to analysts’ expectations of $162.20 million. Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%. Equities analysts predict that Alvotech will post -0.07 earnings per share for the current year.

Institutional Trading of Alvotech

Several hedge funds and other institutional investors have recently modified their holdings of the company. State of Wyoming acquired a new stake in Alvotech during the third quarter valued at $54,000. ProShare Advisors LLC increased its position in Alvotech by 24.0% in the 4th quarter. ProShare Advisors LLC now owns 13,826 shares of the company’s stock worth $71,000 after purchasing an additional 2,675 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Alvotech by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,211 shares of the company’s stock worth $78,000 after purchasing an additional 3,110 shares in the last quarter. Magnetar Financial LLC purchased a new stake in shares of Alvotech during the 3rd quarter worth about $86,000. Finally, Ulland Investment Advisors LLC acquired a new stake in shares of Alvotech during the 3rd quarter valued at about $92,000.

More Alvotech News

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Q4 and FY‑2025 revenue beat and bullish 2026 outlook — Q4 revenue was $173M (+13% YoY) and FY revenue was $593M (+21% YoY); management reiterated 2026 revenue guidance of $650–700M and raised adjusted EBITDA guidance. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Positive Sentiment: Regulatory approvals, commercial launches and partner deals expand near‑term commercial runway — multiple biosimilars (e.g., AVT05, AVT03) cleared in Europe/UK, a marketing application accepted for AVT23, U.S. launch activity via partners (Selarsdi™), and supply/commercialization agreements with Sandoz for key territories. Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments
• Positive Sentiment: Balance sheet and leadership moves reduce execution risk — Alvotech raised ~\$300M, listed on Nasdaq Stockholm, expanded R&D via acquisitions, and appointed Lisa Graver as CEO and other senior hires to support scaling. Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO
• Neutral Sentiment: U.S. approvals expected late‑2026 but management says they will have minimal 2026 topline impact — this tempers upside from potential FDA wins this year. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage and price‑target dispersion — several buy/overweight ratings and median analyst target near \$9 show upside in some forecasts, but targets vary widely—expect mixed analyst reactions. Alvotech Reports Q4 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Short‑interest data reported for March appears inconsistent/invalid (entries show 0 shares and NaN increases), so short‑interest signals are currently unreliable. (Multiple short‑interest notices 3/18–3/20)
• Negative Sentiment: EPS missed consensus — reported EPS of $0.03 vs. consensus ~$0.13, which can pressure sentiment despite the revenue beat. Alvotech earnings summary
• Negative Sentiment: FDA inspection observations remain an overhang — management says improvements are underway and resubmissions are planned for Q2 2026, but regulatory risk could delay U.S. commercialization and investor confidence. Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).